吉西他滨联合替吉奥与联合顺铂治疗晚期胰腺癌的疗效比较

发布时间：2019-03-25 21:44

【摘要】：目的对比吉西他滨联合替吉奥与吉西他滨联合顺铂治疗晚期胰腺癌的临床疗效与安全性。方法45例晚期胰腺癌患者,随机分为吉西他滨联合替吉奥组(GS组,23例)与吉西他滨联合顺铂组(GP组,22例)。GS组:吉西他滨1 000 mg/m2,第1和8天静脉滴注,替吉奥胶囊75 mg/(m~2·d),第1~14天餐后30 min口服,2次/d,21 d为一周期;GP组:吉西他滨1 000 mg/m2,第1和8天静脉滴注,顺铂25 mg/(m~2·d),第2~4天静脉滴注,21 d为一周期。结果 GS组与GP组疾病控制率(CR+PR+SD)分别为78.3%和72.7%,差异无统计学意义(P0.05)。GS组与GP组中位无疾病进展时间分别为5.75个月和4.50个月(P0.05),中位总生存时间分别为9个月和8个月(P0.05)。两组主要毒副反应为血液学毒性及消化道反应,CP组恶心、呕吐发生率高于GS组,差异有统计学意义(P0.05)。结论吉西他滨联合替吉奥与联合顺铂治疗晚期胰腺癌安全有效,前者较后者毒副发生率低且可耐受,在延长生存期方面有一定优势,但差异无统计学意义。
[Abstract]:Objective to compare the clinical efficacy and safety of gemcitabine combined with teggio and gemcitabine combined with cisplatin in the treatment of advanced pancreatic cancer. Methods 45 patients with advanced pancreatic cancer were randomly divided into gemcitabine combined with teggio group (GS group, 23 cases) and gemcitabine combined with cisplatin group (GP group, 22 cases with). GS group: gemcitabine 1 000 mg/m2, intravenous drip on day 1 and 8). Tigio capsule 75 mg/ (m2 路d), 30 min after meal, twice a day, 21 days, once a cycle); GP group: gemcitabine 1 000 mg/m2, on the 1st and 8th day, cisplatin 25 mg/ (m2 路d), on the 2nd to 4th day, 21 days as a cycle). Results the control rate of (CR PR SD) in GS group and GP group was 78.3% and 72.7%, respectively. There was no significant difference (P 0.05) between). GS group and GP group (P 0.05). The median time of disease-free progression was 5.75 months and 4.50 months respectively (P0.05), and the median total survival time was 9 months and 8 months respectively (P0.05). The incidence of nausea and vomiting in CP group was higher than that in GS group (P0.05). Conclusion gemcitabine combined with tegio and cisplatin are safe and effective in the treatment of advanced pancreatic cancer. The former has lower and tolerable side effects than the latter, and has some advantages in prolonging survival time, but there is no significant difference between the former and cisplatin in the treatment of advanced pancreatic cancer.
【作者单位】：郑州大学第一附属医院肿瘤内科;
【分类号】：R735.9

【相似文献】